Skip to content
value.today

EnteroMedics Inc

Total raised
$21 M
4 rounds on record
Latest round
$3 M
Jul 2018
First round on record
Feb 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of EnteroMedics Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2018$3 MNo. 4$2 to $10 million

EnteroMedics Inc: Raise no. 4, Jul 2018

Investors in this round

5 investors had bought by the notice of Jul 13, 2018: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for EnteroMedics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$12,414
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dan Gladney · Executive Officer, Director
  • Scott Youngstrom · Executive Officer
  • Gary Blackford · Director
  • Jon Tremmel · Director
  • Lori McDougal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in FL, NJ, NY, TX

Remarks in the notice

  • On fees: “H.C. Wainwright received the above sales commission in connection with the private placement of warrants. The HCW Warrants were issued to H.C. Wainwright in connection with a registered direct offering by the Company, which is not reported on this Form D.”
  • On the amounts: “"The warrants and underlying shares of common stock include warrants (i) to purchase 1,241,382 shares of common stock issued to certain institutional investors and (ii) to purchase 86,897 shares of common stock to H.C. Wainwright (""HCW Warrants"")."”

Signed by Scott Youngstrom, Cfo. Source: SEC Form D, newest notice filed Jul 13, 2018. Read the notice at the SEC.

optionsSEC
Jun 2018$2 MNo. 3Under $2 million

EnteroMedics Inc: Raise no. 3, Jun 2018

Investors in this round

5 investors had bought by the notice of Jun 25, 2018: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for EnteroMedics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,108
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dan Gladney · Executive Officer, Director
  • Scott Youngstrom · Executive Officer
  • Gary Blackford · Director
  • Jon Tremmel · Director
  • Lori McDougal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in FL, NJ, NY

Remarks in the notice

  • On fees: “H.C. Wainwright received the above sales commission in connection with the private placement of warrants. The HCW Warrants were issued to H.C. Wainwright in connection with a registered direct offering by the Company, which is not reported on this Form D.”
  • On the amounts: “"The warrants and underlying shares of common stock include warrants (i) to purchase 469,490 shares of common stock issued to certain institutional investors and (ii) to purchase 22,802 shares of common stock to H.C. Wainwright (""HCW Warrants"")."”

Signed by Scott Youngstrom, CFO and Chief Compliance Officer. Source: SEC Form D, newest notice filed Jun 25, 2018. Read the notice at the SEC.

optionsSEC
Jun 2018$1 MNo. 2Under $2 million

EnteroMedics Inc: Raise no. 2, Jun 2018

Investors in this round

4 investors had bought by the notice of Jun 22, 2018: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for EnteroMedics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,809
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dan Gladney · Executive Officer, Director
  • Scott Youngstrom · Executive Officer
  • Gary Blackford · Director
  • Jon Tremmel · Director
  • Lori McDougal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, FL, NJ, NY

Remarks in the notice

  • On fees: “H.C. Wainwright received the above sales commission in connection with the private placement of warrants. The HCW Warrants were issued to H.C. Wainwright in connection with a registered direct offering by the Company, which is not reported on this Form D.”
  • On the amounts: “"The warrants and underlying shares of common stock include warrants (i) to purchase 280,929 shares of common stock issued to certain institutional investors and (ii) to purchase 26,220 shares of common stock to H.C. Wainwright (""HCW Warrants"")."”

Signed by Scott Youngstrom, CFO and Chief Compliance Officer. Source: SEC Form D, newest notice filed Jun 22, 2018. Read the notice at the SEC.

optionsSEC
Oct 2017$61 MIssued in a merger or acquisition$50 to $250 million

EnteroMedics Inc: Private sale, Oct 2017

Investors in this round

13 investors had bought by the notice of Oct 17, 2017: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for EnteroMedics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$61 M of $61 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dan W Gladney · Executive Officer, Director
  • Naqeeb A Ansari · Executive Officer
  • Peter M DeLange · Executive Officer
  • Scott P Youngstrom · Executive Officer
  • Bobby I Griffin · Director
  • Gary D Blackford · Director
  • Jon T Tremmel · Director
  • Lori C McDougal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents: value of common stock issued or convertible from series C convertible preferred stock; the liquidation preference of new preferred stock at $2.748774 per share of common stock; and $5 million cash.”

Signed by Scott P. Youngstrom, CFO and Chief Compliance Officer. Source: SEC Form D, newest notice filed Oct 17, 2017. Read the notice at the SEC.

equitySEC
May 2017$31 MIssued in a merger or acquisition$10 to $50 million

EnteroMedics Inc: Private sale, May 2017

Investors in this round

41 investors had bought by the notice of Jun 5, 2017: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for EnteroMedics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dan W Gladney · Executive Officer, Director
  • Naqeeb A Ansari · Executive Officer
  • Paul F Hickey · Executive Officer
  • Peter M DeLange · Executive Officer
  • Rajesh F Nihalani · Executive Officer
  • Scott P Youngstrom · Executive Officer
  • Bobby I Griffin · Director
  • Carl D Goldfischer · Director
  • Gary D Blackford · Director
  • Jon T Tremmel · Director
  • Lori C McDougal · Director
  • Nicholas L Teti, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents the value of the Issuer's common shares issued in connection with the merger of BarioSurg, Inc., based on the last reported sale price of the Issuer's common shares on NASDAQ Stock Exchange on May 22, 2017 and $2 Million additional cash.”

Signed by Scott P. Youngstrom, CFO and Chief Compliance Officer. Source: SEC Form D, newest notice filed Jun 5, 2017. Read the notice at the SEC.

equitySEC
Feb 2009$16 MNo. 1$10 to $50 million

EnteroMedics Inc: Raise no. 1, Feb 2009

Investors in this round

33 investors had bought by the notice of Feb 27, 2009: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for EnteroMedics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $17 M offered; $1 M still to sell
Smallest investment taken
$5,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$617,444
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation

People named in the notice

  • Adrianus Jos Donders · Executive Officer
  • Greg S Lea · Executive Officer
  • Mark B Knudson · Executive Officer, Director
  • Bobby Ivan Griffin · Director
  • Carl Goldfischer · Director
  • Catherine Friedman · Director
  • Donald C Harrison · Director
  • Ellen Koskinas · Director
  • Jon T Tremmel · Director
  • Luke Evnin · Director
  • Nicholas L Teti · Director
  • Paul Klingenstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Canaccord Adams Inc. (CRD 1020) · Boston, MaSold in no state named

Remarks in the notice

  • On the amounts: “Offering Closed”

Signed by Greg S Lea, Cfo. Source: SEC Form D, newest notice filed Feb 27, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • EnteroMedics Inc chose not to state its revenue in its newest notice of a funding round (Jul 2018).

    SEC Form D · Jul 2018

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jul 2018

That is all the official record says: EnteroMedics Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in EnteroMedics Inc
InvestorKindAmountRoundRoleSource
HealthCor Partners Fund II, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
HealthCor Partners GP, LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
HealthCor Partners II, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
HealthCor Partners Management GP, LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
HealthCor Partners Management LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 33 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by EnteroMedics Inc
NameRoleNamed in
Dan GladneyExecutive officerJul 2018
Scott YoungstromExecutive officerJul 2018
Dan W GladneyExecutive officerOct 2017
Naqeeb A AnsariExecutive officerOct 2017
Peter M DeLangeExecutive officerOct 2017
Scott P YoungstromExecutive officerOct 2017
Paul F HickeyExecutive officerJun 2017
Rajesh F NihalaniExecutive officerJun 2017
Adrianus Jos DondersExecutive officerFeb 2009
Greg S LeaExecutive officerFeb 2009
Mark B KnudsonExecutive officerFeb 2009
Dan GladneyDirectorJul 2018
Gary BlackfordDirectorJul 2018
Jon TremmelDirectorJul 2018
Lori McDougalDirectorJul 2018
Bobby I GriffinDirectorOct 2017
Dan W GladneyDirectorOct 2017
Gary D BlackfordDirectorOct 2017
Jon T TremmelDirectorOct 2017
Lori C McDougalDirectorOct 2017
Carl D GoldfischerDirectorJun 2017
Nicholas L Teti, Jr.DirectorJun 2017
Bobby Ivan GriffinDirectorFeb 2009
Carl GoldfischerDirectorFeb 2009
Catherine FriedmanDirectorFeb 2009
Donald C HarrisonDirectorFeb 2009
Ellen KoskinasDirectorFeb 2009
Luke EvninDirectorFeb 2009
Mark B KnudsonDirectorFeb 2009
Nicholas L TetiDirectorFeb 2009
Paul KlingensteinDirectorFeb 2009